Post-IPO stock offer preps Supernus for launch of epilepsy drugs
This article was originally published in Scrip
Executive Summary
Supernus Pharmaceuticals has priced an underwritten public offering of six million shares of common stock at $8 per share for net proceeds of $44.7 million for the commercial launch of the newly public company's epilepsy drugs Oxtellar XR and Trokendi XR, clinical development of Phase II attention-deficit hyperactivity disorder (ADHD) drug candidates SPN-810 and SPN-812, and repayment of debt and other expenses.